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Article / Clinical Case Report
Abstract
There is scarce knowledge on early intestinal obstruction in Crohn’s disease (CD) after infliximab treatment. Therefore, 
we describe two cases of early intestinal obstruction in a series of 46 CD patients treated with infliximab. Both our two 
cases were 21-year-old men with newly diagnosed CD who were diagnosed with perianal disease 2 years previously. 
They were suffering from diarrhea and abdominal pain, but there were no symptoms indicating bowel obstruction. 
Radiographic studies revealed stenotic sites in the terminal ileum in both cases. In both cases, infliximab 300 mg was 
infused, after which their abnormal laboratory data as well as symptoms such as diarrhea and abdominal pain clearly 
improved. However, on the 11th or 13th day post-treatment, they presented abdominal distension with air-fluid levels 
on imaging studies. Ileocolonic resection was performed in both cases. Early intestinal obstruction after infliximab therapy 
is characterized by initial improvement of the symptoms and the laboratory data, which is soon followed by clinical 
deterioration. This outcome indicates that infliximab is so swiftly effective that the healing process tapers the stenotic 
site, resulting in bowel obstruction. Thus, although unpleasant and severe, the obstruction cannot be considered as a side 
effect but rather a consequence of infliximab’s efficacy. CD patients with intestinal stricture, particularly the penetrating 
type with stricture, should be well informed about the risk of developing intestinal obstruction after infliximab therapy 
and the eventual need for surgical intervention.
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INTRODUCTION
Infliximab was the first monoclonal antibody 
biologic drug used to treat Crohn’s disease (CD), 
and it revolutionized therapeutic modalities for the 
disease. We consider inflammatory bowel disease to 
be a lifestyle disease mainly mediated by a westernized 
diet.1 In this regard, we developed a plant-based 
diet as a countermeasure against the westernized 
diet.1 We administered infliximab together with 
a plant-based diet as first-line (IPF) therapy on 
an inpatient basis in 46 CD patients (A1 below 
16 y: 6; A2 between 17 and 40 y: 33; A3 above 
40 y: 7; L1 Ileal: 1; L2 Colonic: 13; L3 Ileocolonic 32; 
B1 Nonstricturing/nonpenetrating: 33; B2 Stricturing: 
12; B3 Penetrating: 1; p perianal disease modifier: 33).2 
Our plant-based diet was a lacto-ovo-vegetarian diet 
with fish once a week and meat every other week.1 
Plant-based diets prevent chronic diseases and bring 
longevity. Therefore, they are recommended to the 
public.2 All patients achieved clinical remission by week 
6 after the first infliximab infusion, except for two 
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patients who experienced obstruction within 2 weeks 
following the first infliximab infusion.2,3 Our protocol 
using inf l ix imab2 brought early improvement 
compared to the administration of adalimumab.4 
Mean Crohn’s Disease Activity Index (CDAI) scores were 
314, 163, and 115 at baseline and weeks 1 and 2, 
respectively, for the infliximab group.2 The scores 
for the adalimumab group were 313, 264, and 232, 
respectively.4
There have been brief statements or abstracts 
in the literature reporting early intestinal obstruction 
requiring surgical treatment after infliximab treatment 
in Crohn’s disease,5-7 but no precise reports are found.
CASE REPORT
Case 1
A 21-year-old man was referred because of a 
perirectal abscess followed by right lower quadrant 
abdominal pain and diarrhea. The initial diagnostic 
workup revealed the cobblestone appearance of the 
mucosa and fissurings in the right colon (Figure 1), 
leading to a diagnosis of CD. At that time, his BMI was 
19.8 after losing 6 kg in the previous 7 months. Physical 
examination was non-contributory, except for anal 
skin tags and a perianal fistula scar. Laboratory data 
revealed abnormalities consistent with CD (Table 1). 
Plain film of the abdomen showed an isolated air-fluid 
level (Figure 2A), but he did not have symptoms 
indicating an intestinal obstruction. Therefore, routine 
examination and treatment for CD were performed.2
The patient received liquid infusion without meals 
during morphological studies to assess clinical types 
and intestinal stenosis. Enteroclysis revealed stenotic 
portions and longitudinal ulcers in the distal portion 
of the ileum (Figure 2C). On the 8th hospital day, 
infliximab 300 mg (Remicade 5 mg/kg; Centocor, 
Malvern, PA, USA) was infused.8 A plant-based diet1,2 
(1700 kcal/day) was initiated on the day after the 
infusion. Laboratory data 1 week after the infusion 
showed apparent improvement (Table 1), and the 
patient felt better after the 1st infusion of infliximab. 
However, on the 13th day, he presented abdominal 
distension after the first infusion. Intestinal obstruction 
was diagnosed due to clear air-fluid levels on plain 
abdominal radiographs (Figure 2B).
At this point, the erythrocyte sedimentation rate 
was further improved, but C-reactive protein (CRP) 
concentration was elevated (Table 1). The 2nd infusion8 
was cancelled, and the patient underwent ileocolonic 
resection 2 weeks later. Critical stenosis was found 
in the terminal ileum at 40 cm from the ileocecal 
valve. Perioperative endoscopy did not reveal another 
stenotic site proximally. The resected specimen 
showed round ulcers at the proximal site and a 
longitudinal ulcer of approximately 30 cm (Figure 3). 
The pathological findings were consistent with CD, 
namely, non-caseating epithelioid cell granulomas. 
A registered dietitian designed dietary guidance on 
a plant-based diet before discharge, and he was 
prescribed mesalazine, 2.25 g/day.
Figure 1. Double-contrast barium enema of the colon 
showing inflammation of the ascending colon and the 
cecum. The bowel is narrowed at the lower portion of 
the ascending colon. Cobblestone appearance is seen in 
the upper portion of the ascending colon. Fissurings are 
indicated by arrows.
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He was followed up every 8 weeks. Endoscopic 
remission was ascertained after 4 years of follow 
up, and medication was withdrawn 3 years later. 
The patient completed 13 years of follow-up, with 
normal laboratory tests, and no complications. 
His plant-based diet score,9 which evaluates adherence 
to the plant-based diet, was –2 before admission, 
followed by 38 and 20 out of 40 at 2 years and 9 years 
after discharge, respectively.
Case 2
A 21-year-old man was referred because of a 
long-lasting draining anal fistula, followed by diarrhea 
and abdominal pain. Colonoscopy revealed skipped 
Figure 2. Plain abdominal radiographs on admission (A) and 13 days after the first infusion of infliximab (B). Solitary 
air-fluid level is indicated by an arrow (A). Multiple air-fluid levels are seen (B); C – Picture of the enteroclysis. 
Two stenotic portions are observed in the distal part of the ileum (white arrows). At the sites of stenosis, white soft 
shadows are seen (hollowed arrows) indicating active ulcers. Pre-stenotic dilatation is not observed. Longitudinal 
ulcers are observed (arrowheads).
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lesions in the colon and longitudinal ulcers in the 
sigmoid. Non-caseating epithelioid cell granuloma was 
found in the biopsy specimen. Barium enema study 
revealed shortening of the right colon, stenotic sites, 
fistulas in the terminal ileum (Figure 4), and a diffuse 
coarse mucosa from the sigmoid to the distal part of 
the descending colon (Figure 4A). He was diagnosed as 
having CD. After losing 10 kg over the last 4 months, 
his BMI was 18.9. The physical examination was 
unremarkable, except for an anal fistula. Laboratory 
data revealed an elevated CRP concentration, marked 
anemia, and moderate hypoalbuminemia (Table 1). 
Plain film of the abdomen was unremarkable, however, 
enteroclysis revealed entero-enteric fistulas and 
stenotic sites in the distal ileum (Figure 4B). On the 
5th hospitalization day, 300 mg of infliximab was 
infused.
A  p lan t -based  d ie t  (800  kca l /day )  was 
concomitantly started. Laboratory data 5 days after the 
infusion showed apparent improvement (Table 1). He 
felt better after the 1st infusion of infliximab. His caloric 
intake increased to 1100 kcal and then 1400 kcal/
day. However, he complained of abdominal distension 
and vomiting on the 11th day after the first infusion. 
Radiographic signs of intestinal obstruction were found 
(Figure 5A), and meals were withdrawn. At this point, 
CRP normalized and CDAI10 decreased from 377 to 
115, which is considered to be remission (Table 1). 
The standard infliximab induction therapy8 proceeded 
to preserve the left colon. Colonoscopy after the 3rd 
infusion revealed endoscopic remission in the left colon 
including scars of the longitudinal ulcers in the sigmoid 
colon. Resumption of meals (800 kcal/day) resulted in 
Figure 3. Gross examination of the resected specimen 
of case 1. Two round ulcers at the proximal site 
(arrowheads) and a longitudinal ulcer of 30 cm (arrows) 
are seen in the terminal ileum. Cobblestone appearance 
is seen in the ascending colon. The appendix (Ap) is 
swollen.
Table 1. Change in laboratory data after infliximab (IFX) treatment
Item Normal range
Case 1 Case 2
Before 
IFX
After IFX Before 
  IFX
After IFX
1 week 13 days 5 days 11 days
CRP ≤0.3 mg/dL 3.6 1.0 2.9 5.5 1.8 0.2
ESR <15 mm/hr 84 38 23 40 43 27
Hb 13.8-17.5 g/dL 12.2 12.3 12.5 7.9 8.6 8.8
WBC 3900-8800/mm3 7700 7800 4900 6000 3400 3600
Platelets 15.2-31.4x104/mm3 56.2 42.0 42.3 87.0 69.5 56.0
T. protein 6.7-8.2 g/dL 7.9 7.3 6.7 7.4 6.7 6.5
Albumin 3.8-5.2 mg/dL 4.0 4.0 3.7 2.8 2.8 3.1
T. cholesterol 110-220 mg/dL 147 139 120 124 95 110
α2-globulin 4.8-8.6% 13.7 10.5 10.1 14.0 12.1 10.2
FOB <200 ng/mL 153 n.a. 211 154 28 820
CDAI n.a. 377 183 115
CDAI = Crohn disease activity index; CRP = C-reactive protein; ESR = erythrocyte sedimentation rate; FOB = fecal occult 
blood; Hb = hemoglobin; IFX; infliximab; n.a. = not available; T. cholesterol = Total cholesterol; T. protein = total protein; 
WBC = white blood cells.
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Figure 4. Double-contrast barium enema study. Entire picture of the colon (A) and enlarged picture of the ileocolic 
portion (B). A – Shortening of the right colon is seen. Diffuse coarse mucosa from the sigmoid colon to the distal 
part of the descending colon is observed. B - Two stenotic sites in the terminal ileum are indicated by white arrows. 
There are two entero-enteric fistulas indicated by F. TC, transverse colon; AC, ascending colon; TI, terminal ileum; 
F, fistula.
Figure 5. Plain abdominal radiographs on the 11th day after the first infusion of infliximab (A) and the day following 
resumption of meals after the 3rd infliximab infusion (B). Air-fluid levels are indicated by arrows (A).
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repetition of abdominal distension and air-fluid level 
on the following day (Figure 5B).
He then underwent surgery. There were adhesions 
of the ileum and colon and ileocolonic fistulas 
(i leum-ascending colon, i leum-sigmoid colon). 
He underwent ileo-right hemicolonic resection 
with side (the ileum) to side (the transverse colon) 
anastomosis and partial sigmoidectomy. The resected 
specimen showed longitudinal ulcers in the ileum and 
colon (Figure 6).
Consider ing the s igns of poor prognosis 
(penetrating type of CD, association of anal fistula, onset 
at a young age, and terminal ileal involvement),11-13 
scheduled maintenance therapy with infliximab14 
was initiated. A few months later, although there 
were no symptoms, colonoscopy was performed 
because CRP had increased from 0.3 to 1.0 mg/dL 
and fecal occult blood test had deteriorated from 
759 ng/mL to >1000 ng/mL. Endoscopic relapse, i.e., 
shallow circular ulceration at the site of anastomosis, 
was observed. Azathioprine (50 mg/day) was added to 
the therapeutic regimen. The patient has maintained 
clinical remission for nearly 6 years to the present 
(with 45 courses of infliximab). His CRP concentration 
was normal on six of seven occasions in the latest year, 
and fecal occult blood tests were negative on all seven 
occasions. We plan to stop infliximab maintenance 
therapy when he achieves successive normal CRP 
concentrations and negative fecal occult blood tests for 
2 years. His plant-based diet score was 6 of 40 before 
admission and 24 of 40 at 27 months after discharge.
DISCUSSION
Lichtenstein et al.15 reported that infliximab 
therapy per se did not increase intestinal stenosis, 
stricture, or obstruction (SSOs) in CD. In their study, 
however, SSOs that did not necessitate surgery were 
included and the observation period extended to 
1.8 years. There is no description of early development 
of obstruction necessitating surgery in their report.15
The intervals from inf l ix imab infusion to 
development of an obstruction in our two cases 
were 11 and 13 days. In our cases, symptoms and 
laboratory data clearly improved after infliximab 
therapy (Table 1). The induction treatment with 
adalimumab did not obstruct any of the 97 patients 
with symptomatic small bowel stricture.16 Adalimumab 
was then switched to infliximab in 35 nonresponders. 
Eight out of these 35 patients subsequently required 
Figure 6. Gross examination of the resected specimen of the case 2. The terminal ileum is fixed to the ascending 
colon by adhesion through fistulas. They were removed en bloc. Arrows indicate longitudinal ulcers (scar).
Chiba M, Tanaka Y, Ono I
7-8Autops Case Rep (São Paulo). 2019;9(1):e2018068
intestinal resection. The exact timing of the resections 
is not described.16 On the other hand, infliximab 
caused intestinal obstruction necessitating surgery 
in four of six patients with symptomatic small bowel 
stricture.17 Two patients underwent surgery 10 days 
after infliximab due to deterioration. The other 
two patients showed symptomatic relief first but 
deteriorated later, resulting in resection within 8 weeks 
after infliximab.17 Clinical improvement was achieved 
using infliximab in all 17 cases reported by Toy et al.6 
and in all seven cases reported by Vasilopoulos et al.7 
before obstructive symptoms appeared. Therefore, 
our observation together with others6,7,17 supports the 
interpretation that infliximab is so swiftly effective in 
healing ulcers18 that the healing process narrows, even 
more, the stenotic site, resulting in bowel obstruction. 
Early obstruction after infliximab administration cannot 
be categorized as a conventional side effect, but 
rather as an event due to the efficacy of infliximab. 
It is unlikely that the plant-based diet per se induced 
intestinal obstruction because the obstruction occurred 
in similar chronologic fashion in the absence of the 
plant-based diet.6,7,17
Considering that the early obstruction after 
infliximab administration was due to the efficacy of 
infliximab, IPF therapy was effective in all 46 cases.2 
This supports our rationale of IPF therapy: infliximab as 
first-line treatment and incorporation of a plant-based 
diet.2 Immunomodulators were not needed for 
induction of remission in our IPF therapy.
When biologics and/or immunomodulators 
should be withdrawn is an unsolved issue.19 CD is 
relentless. The stable quiescent phase is ascertained 
by clinical remission and normal biomarkers (CRP, 
fecal occult blood). If these conditions last for 2 years 
and morphological remission is ascertained with 
endoscopy, we believe that relapse is unlikely to occur. 
Therefore, we withdraw infliximab first. If clinical 
course is uneventful for the next few years, then 
azathioprine is withdrawn.
In the absence of signs of obstruction, stricture 
per se is no longer regarded as a contraindication for 
infliximab therapy.20,21 Indeed, no obstruction occurred 
after infliximab treatment in our 11-case series of 
patients with stricture.2 If bowel obstruction happens 
after infliximab therapy, it is surgically treated without 
any disadvantages due to infliximab use.22,23 Infliximab 
use may be an advantage in terms of improving the 
patient’s clinical condition because the obstruction 
will not occur if infliximab is ineffective.7 It is critical 
that CD patients with stricture, and particularly CD 
patients with the penetrating type like case 2 of this 
report, are fully informed about the risk of intestinal 
obstruction necessitating surgery prior to initiating 
infliximab therapy.
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